nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Ethanolamine Oleate—Orlistat—obesity	0.623	1	CrCrCtD
Alprostadil—Ethanolamine Oleate—FABP4—obesity	0.00357	0.737	CrCbGaD
Alprostadil—PTGIR—hindbrain—obesity	0.00334	0.0667	CbGeAlD
Alprostadil—PTGER2—adrenal cortex—obesity	0.00292	0.0584	CbGeAlD
Alprostadil—PTGER2—adipose tissue—obesity	0.00235	0.047	CbGeAlD
Alprostadil—PTGER2—adrenal gland—obesity	0.00211	0.0422	CbGeAlD
Alprostadil—PTGIR—respiratory system—obesity	0.00204	0.0408	CbGeAlD
Alprostadil—SLCO2A1—islet of Langerhans—obesity	0.00189	0.0377	CbGeAlD
Alprostadil—SLCO2A1—respiratory system—obesity	0.00178	0.0356	CbGeAlD
Alprostadil—PTGER1—endocrine gland—obesity	0.00174	0.0347	CbGeAlD
Alprostadil—PTGIR—cardiovascular system—obesity	0.00156	0.0312	CbGeAlD
Alprostadil—SLCO2A1—adrenal cortex—obesity	0.0015	0.0299	CbGeAlD
Alprostadil—PTGIR—adipose tissue—obesity	0.00138	0.0275	CbGeAlD
Alprostadil—PTGIR—digestive system—obesity	0.0013	0.0259	CbGeAlD
Alprostadil—SLCO2B1—respiratory system—obesity	0.00128	0.0255	CbGeAlD
Alprostadil—PTGIR—adrenal gland—obesity	0.00124	0.0247	CbGeAlD
Alprostadil—SLCO3A1—pituitary gland—obesity	0.00122	0.0244	CbGeAlD
Alprostadil—SLCO3A1—adipose tissue—obesity	0.00122	0.0243	CbGeAlD
Alprostadil—SLCO2A1—pituitary gland—obesity	0.00121	0.0242	CbGeAlD
Alprostadil—SLCO2A1—adipose tissue—obesity	0.0012	0.0241	CbGeAlD
Alprostadil—ABCC5—pituitary gland—obesity	0.00111	0.0221	CbGeAlD
Alprostadil—ABCC5—adipose tissue—obesity	0.0011	0.022	CbGeAlD
Alprostadil—SLCO3A1—adrenal gland—obesity	0.00109	0.0218	CbGeAlD
Alprostadil—SLCO2A1—adrenal gland—obesity	0.00108	0.0216	CbGeAlD
Alprostadil—PTGIR—endocrine gland—obesity	0.00107	0.0214	CbGeAlD
Alprostadil—ABCC5—adrenal gland—obesity	0.000988	0.0197	CbGeAlD
Alprostadil—PTGIR—liver—obesity	0.000967	0.0193	CbGeAlD
Alprostadil—SLCO3A1—endocrine gland—obesity	0.000946	0.0189	CbGeAlD
Alprostadil—SLCO2A1—endocrine gland—obesity	0.000937	0.0187	CbGeAlD
Alprostadil—SLCO2B1—adipose tissue—obesity	0.000862	0.0172	CbGeAlD
Alprostadil—SLCO3A1—liver—obesity	0.000853	0.017	CbGeAlD
Alprostadil—SLCO2A1—liver—obesity	0.000845	0.0169	CbGeAlD
Alprostadil—SLCO2B1—digestive system—obesity	0.000812	0.0162	CbGeAlD
Alprostadil—SLCO2B1—adrenal gland—obesity	0.000774	0.0155	CbGeAlD
Alprostadil—ABCC5—liver—obesity	0.000773	0.0154	CbGeAlD
Alprostadil—ABCC4—adipose tissue—obesity	0.000764	0.0153	CbGeAlD
Alprostadil—ABCC4—digestive system—obesity	0.000719	0.0144	CbGeAlD
Alprostadil—ABCC4—adrenal gland—obesity	0.000685	0.0137	CbGeAlD
Alprostadil—SLCO2B1—endocrine gland—obesity	0.000671	0.0134	CbGeAlD
Alprostadil—SLCO2B1—liver—obesity	0.000605	0.0121	CbGeAlD
Alprostadil—ABCC4—endocrine gland—obesity	0.000594	0.0119	CbGeAlD
Alprostadil—ABCC4—liver—obesity	0.000536	0.0107	CbGeAlD
Alprostadil—Dry mouth—Diethylpropion—obesity	0.000426	0.0026	CcSEcCtD
Alprostadil—Dyspepsia—Phentermine—obesity	0.000423	0.00258	CcSEcCtD
Alprostadil—Headache—Methamphetamine—obesity	0.000419	0.00255	CcSEcCtD
Alprostadil—Mydriasis—Topiramate—obesity	0.000415	0.00253	CcSEcCtD
Alprostadil—Nasal congestion—Bupropion—obesity	0.000414	0.00252	CcSEcCtD
Alprostadil—Feeling abnormal—Phenylpropanolamine—obesity	0.000414	0.00252	CcSEcCtD
Alprostadil—Cardiac arrest—Sibutramine—obesity	0.000411	0.00251	CcSEcCtD
Alprostadil—Injury—Bupropion—obesity	0.00041	0.0025	CcSEcCtD
Alprostadil—Tachycardia—Diethylpropion—obesity	0.000408	0.00249	CcSEcCtD
Alprostadil—Hypokalaemia—Orlistat—obesity	0.000407	0.00248	CcSEcCtD
Alprostadil—Blood creatinine increased—Sibutramine—obesity	0.000405	0.00247	CcSEcCtD
Alprostadil—Hyperhidrosis—Diethylpropion—obesity	0.000404	0.00246	CcSEcCtD
Alprostadil—Headache—Benzphetamine—obesity	0.000404	0.00246	CcSEcCtD
Alprostadil—Diarrhoea—Phendimetrazine—obesity	0.000402	0.00245	CcSEcCtD
Alprostadil—Hypokalaemia—Sibutramine—obesity	0.000394	0.0024	CcSEcCtD
Alprostadil—Thrombocytopenia—Cimetidine—obesity	0.000389	0.00237	CcSEcCtD
Alprostadil—Dizziness—Phendimetrazine—obesity	0.000389	0.00237	CcSEcCtD
Alprostadil—Tachycardia—Cimetidine—obesity	0.000388	0.00237	CcSEcCtD
Alprostadil—Hypoglycaemia—Bupropion—obesity	0.000386	0.00235	CcSEcCtD
Alprostadil—Influenza—Orlistat—obesity	0.000386	0.00235	CcSEcCtD
Alprostadil—Lethargy—Bupropion—obesity	0.000385	0.00234	CcSEcCtD
Alprostadil—Nausea—Benzphetamine—obesity	0.000383	0.00233	CcSEcCtD
Alprostadil—Sensory loss—Topiramate—obesity	0.000382	0.00233	CcSEcCtD
Alprostadil—Abdominal pain—Phentermine—obesity	0.00038	0.00232	CcSEcCtD
Alprostadil—Ethanolamine Oleate—CYP2E1—obesity	0.00038	0.0785	CrCbGaD
Alprostadil—Pain in extremity—Bupropion—obesity	0.000377	0.0023	CcSEcCtD
Alprostadil—Vasodilation—Topiramate—obesity	0.000377	0.00229	CcSEcCtD
Alprostadil—Vasodilation procedure—Topiramate—obesity	0.000377	0.00229	CcSEcCtD
Alprostadil—Sweating increased—Orlistat—obesity	0.000376	0.00229	CcSEcCtD
Alprostadil—Influenza—Sibutramine—obesity	0.000374	0.00228	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Topiramate—obesity	0.000369	0.00225	CcSEcCtD
Alprostadil—Headache—Phendimetrazine—obesity	0.000368	0.00224	CcSEcCtD
Alprostadil—Dyspepsia—Diethylpropion—obesity	0.000368	0.00224	CcSEcCtD
Alprostadil—Bronchitis—Sibutramine—obesity	0.000359	0.00219	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Orlistat—obesity	0.000359	0.00219	CcSEcCtD
Alprostadil—Nausea—Phendimetrazine—obesity	0.000349	0.00213	CcSEcCtD
Alprostadil—Pollakiuria—Sibutramine—obesity	0.000345	0.0021	CcSEcCtD
Alprostadil—Asthenia—Phentermine—obesity	0.000345	0.0021	CcSEcCtD
Alprostadil—Feeling abnormal—Diethylpropion—obesity	0.000344	0.0021	CcSEcCtD
Alprostadil—Renal failure—Orlistat—obesity	0.000338	0.00206	CcSEcCtD
Alprostadil—Hyperglycaemia—Sibutramine—obesity	0.000337	0.00205	CcSEcCtD
Alprostadil—Urinary tract infection—Orlistat—obesity	0.000335	0.00204	CcSEcCtD
Alprostadil—Dinoprostone—SLC22A1—obesity	0.000334	0.0691	CrCbGaD
Alprostadil—Dizziness—Phenylpropanolamine—obesity	0.000332	0.00202	CcSEcCtD
Alprostadil—Diarrhoea—Phentermine—obesity	0.000329	0.002	CcSEcCtD
Alprostadil—Acute coronary syndrome—Sibutramine—obesity	0.000328	0.002	CcSEcCtD
Alprostadil—Feeling abnormal—Cimetidine—obesity	0.000328	0.002	CcSEcCtD
Alprostadil—Renal failure—Sibutramine—obesity	0.000328	0.002	CcSEcCtD
Alprostadil—Myocardial infarction—Sibutramine—obesity	0.000327	0.00199	CcSEcCtD
Alprostadil—Influenza—Bupropion—obesity	0.000326	0.00199	CcSEcCtD
Alprostadil—Urinary tract infection—Sibutramine—obesity	0.000324	0.00197	CcSEcCtD
Alprostadil—Sinusitis—Orlistat—obesity	0.000323	0.00197	CcSEcCtD
Alprostadil—Influenza like illness—Topiramate—obesity	0.000321	0.00196	CcSEcCtD
Alprostadil—Dizziness—Phentermine—obesity	0.000318	0.00194	CcSEcCtD
Alprostadil—Haematuria—Sibutramine—obesity	0.000318	0.00194	CcSEcCtD
Alprostadil—Sweating increased—Bupropion—obesity	0.000317	0.00193	CcSEcCtD
Alprostadil—Rash—Phenylpropanolamine—obesity	0.000317	0.00193	CcSEcCtD
Alprostadil—Dermatitis—Phenylpropanolamine—obesity	0.000316	0.00193	CcSEcCtD
Alprostadil—Body temperature increased—Cimetidine—obesity	0.000314	0.00192	CcSEcCtD
Alprostadil—Bronchitis—Bupropion—obesity	0.000313	0.00191	CcSEcCtD
Alprostadil—Sinusitis—Sibutramine—obesity	0.000313	0.00191	CcSEcCtD
Alprostadil—Haemoglobin—Orlistat—obesity	0.000311	0.00189	CcSEcCtD
Alprostadil—Haemorrhage—Orlistat—obesity	0.000309	0.00188	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—obesity	0.000309	0.0638	CrCbGaD
Alprostadil—Pharyngitis—Orlistat—obesity	0.000307	0.00187	CcSEcCtD
Alprostadil—Bradycardia—Sibutramine—obesity	0.000305	0.00186	CcSEcCtD
Alprostadil—Cramps of lower extremities—Topiramate—obesity	0.000304	0.00185	CcSEcCtD
Alprostadil—Urethral disorder—Orlistat—obesity	0.000303	0.00185	CcSEcCtD
Alprostadil—Rash—Phentermine—obesity	0.000303	0.00185	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Bupropion—obesity	0.000303	0.00185	CcSEcCtD
Alprostadil—Dermatitis—Phentermine—obesity	0.000303	0.00184	CcSEcCtD
Alprostadil—Headache—Phentermine—obesity	0.000301	0.00183	CcSEcCtD
Alprostadil—Pollakiuria—Bupropion—obesity	0.000301	0.00183	CcSEcCtD
Alprostadil—Haemoglobin—Sibutramine—obesity	0.000301	0.00183	CcSEcCtD
Alprostadil—Rhinitis—Sibutramine—obesity	0.0003	0.00183	CcSEcCtD
Alprostadil—Haemorrhage—Sibutramine—obesity	0.000299	0.00182	CcSEcCtD
Alprostadil—Nausea—Phenylpropanolamine—obesity	0.000298	0.00182	CcSEcCtD
Alprostadil—Hypoaesthesia—Sibutramine—obesity	0.000298	0.00181	CcSEcCtD
Alprostadil—Pharyngitis—Sibutramine—obesity	0.000297	0.00181	CcSEcCtD
Alprostadil—Hyperglycaemia—Bupropion—obesity	0.000294	0.00179	CcSEcCtD
Alprostadil—Abnormal vision—Topiramate—obesity	0.000289	0.00176	CcSEcCtD
Alprostadil—Visual impairment—Sibutramine—obesity	0.000288	0.00176	CcSEcCtD
Alprostadil—Acute coronary syndrome—Bupropion—obesity	0.000286	0.00175	CcSEcCtD
Alprostadil—Diarrhoea—Diethylpropion—obesity	0.000286	0.00174	CcSEcCtD
Alprostadil—Nausea—Phentermine—obesity	0.000285	0.00174	CcSEcCtD
Alprostadil—Asthenia—Cimetidine—obesity	0.000285	0.00174	CcSEcCtD
Alprostadil—Myocardial infarction—Bupropion—obesity	0.000285	0.00174	CcSEcCtD
Alprostadil—Urinary tract infection—Bupropion—obesity	0.000282	0.00172	CcSEcCtD
Alprostadil—Dizziness—Diethylpropion—obesity	0.000276	0.00168	CcSEcCtD
Alprostadil—Diabetes mellitus—Topiramate—obesity	0.000276	0.00168	CcSEcCtD
Alprostadil—Sinusitis—Bupropion—obesity	0.000273	0.00166	CcSEcCtD
Alprostadil—Diarrhoea—Cimetidine—obesity	0.000272	0.00166	CcSEcCtD
Alprostadil—Nasal congestion—Topiramate—obesity	0.000264	0.00161	CcSEcCtD
Alprostadil—Rash—Diethylpropion—obesity	0.000264	0.00161	CcSEcCtD
Alprostadil—Dermatitis—Diethylpropion—obesity	0.000263	0.0016	CcSEcCtD
Alprostadil—Dizziness—Cimetidine—obesity	0.000263	0.0016	CcSEcCtD
Alprostadil—Haemoglobin—Bupropion—obesity	0.000262	0.0016	CcSEcCtD
Alprostadil—Headache—Diethylpropion—obesity	0.000262	0.0016	CcSEcCtD
Alprostadil—Rhinitis—Bupropion—obesity	0.000261	0.00159	CcSEcCtD
Alprostadil—Haemorrhage—Bupropion—obesity	0.000261	0.00159	CcSEcCtD
Alprostadil—Back pain—Orlistat—obesity	0.00026	0.00159	CcSEcCtD
Alprostadil—Hypoaesthesia—Bupropion—obesity	0.000259	0.00158	CcSEcCtD
Alprostadil—Pharyngitis—Bupropion—obesity	0.000259	0.00158	CcSEcCtD
Alprostadil—Muscle spasms—Orlistat—obesity	0.000259	0.00158	CcSEcCtD
Alprostadil—Urethral disorder—Bupropion—obesity	0.000256	0.00156	CcSEcCtD
Alprostadil—Nervousness—Sibutramine—obesity	0.000253	0.00154	CcSEcCtD
Alprostadil—Back pain—Sibutramine—obesity	0.000252	0.00154	CcSEcCtD
Alprostadil—Visual impairment—Bupropion—obesity	0.000251	0.00153	CcSEcCtD
Alprostadil—Rash—Cimetidine—obesity	0.000251	0.00153	CcSEcCtD
Alprostadil—Dermatitis—Cimetidine—obesity	0.000251	0.00153	CcSEcCtD
Alprostadil—Muscle spasms—Sibutramine—obesity	0.00025	0.00153	CcSEcCtD
Alprostadil—Headache—Cimetidine—obesity	0.000249	0.00152	CcSEcCtD
Alprostadil—Dinoprostone—CYP19A1—obesity	0.000249	0.0514	CrCbGaD
Alprostadil—Nausea—Diethylpropion—obesity	0.000248	0.00151	CcSEcCtD
Alprostadil—Hypoglycaemia—Topiramate—obesity	0.000246	0.0015	CcSEcCtD
Alprostadil—Lethargy—Topiramate—obesity	0.000245	0.00149	CcSEcCtD
Alprostadil—Flushing—Bupropion—obesity	0.000242	0.00148	CcSEcCtD
Alprostadil—Anaemia—Sibutramine—obesity	0.000241	0.00147	CcSEcCtD
Alprostadil—Pain in extremity—Topiramate—obesity	0.00024	0.00146	CcSEcCtD
Alprostadil—Nausea—Cimetidine—obesity	0.000236	0.00144	CcSEcCtD
Alprostadil—Cough—Orlistat—obesity	0.000235	0.00143	CcSEcCtD
Alprostadil—Syncope—Sibutramine—obesity	0.000234	0.00142	CcSEcCtD
Alprostadil—Convulsion—Orlistat—obesity	0.000233	0.00142	CcSEcCtD
Alprostadil—Loss of consciousness—Sibutramine—obesity	0.000229	0.00139	CcSEcCtD
Alprostadil—Cough—Sibutramine—obesity	0.000227	0.00138	CcSEcCtD
Alprostadil—Discomfort—Orlistat—obesity	0.000226	0.00138	CcSEcCtD
Alprostadil—Convulsion—Sibutramine—obesity	0.000226	0.00138	CcSEcCtD
Alprostadil—Blood creatinine increased—Topiramate—obesity	0.000225	0.00137	CcSEcCtD
Alprostadil—Hypertension—Sibutramine—obesity	0.000225	0.00137	CcSEcCtD
Alprostadil—Dry mouth—Orlistat—obesity	0.000224	0.00137	CcSEcCtD
Alprostadil—Nervousness—Bupropion—obesity	0.00022	0.00134	CcSEcCtD
Alprostadil—Oedema—Orlistat—obesity	0.00022	0.00134	CcSEcCtD
Alprostadil—Back pain—Bupropion—obesity	0.00022	0.00134	CcSEcCtD
Alprostadil—Discomfort—Sibutramine—obesity	0.000219	0.00133	CcSEcCtD
Alprostadil—Hypokalaemia—Topiramate—obesity	0.000219	0.00133	CcSEcCtD
Alprostadil—Muscle spasms—Bupropion—obesity	0.000218	0.00133	CcSEcCtD
Alprostadil—Infection—Orlistat—obesity	0.000218	0.00133	CcSEcCtD
Alprostadil—Dry mouth—Sibutramine—obesity	0.000217	0.00132	CcSEcCtD
Alprostadil—Skin disorder—Orlistat—obesity	0.000213	0.0013	CcSEcCtD
Alprostadil—Oedema—Sibutramine—obesity	0.000213	0.0013	CcSEcCtD
Alprostadil—Hyperhidrosis—Orlistat—obesity	0.000212	0.00129	CcSEcCtD
Alprostadil—Infection—Sibutramine—obesity	0.000211	0.00129	CcSEcCtD
Alprostadil—Anaemia—Bupropion—obesity	0.00021	0.00128	CcSEcCtD
Alprostadil—Shock—Sibutramine—obesity	0.000209	0.00127	CcSEcCtD
Alprostadil—Thrombocytopenia—Sibutramine—obesity	0.000208	0.00127	CcSEcCtD
Alprostadil—Tachycardia—Sibutramine—obesity	0.000207	0.00126	CcSEcCtD
Alprostadil—Skin disorder—Sibutramine—obesity	0.000206	0.00126	CcSEcCtD
Alprostadil—Hyperhidrosis—Sibutramine—obesity	0.000205	0.00125	CcSEcCtD
Alprostadil—Syncope—Bupropion—obesity	0.000204	0.00124	CcSEcCtD
Alprostadil—Sweating increased—Topiramate—obesity	0.000202	0.00123	CcSEcCtD
Alprostadil—Bronchitis—Topiramate—obesity	0.0002	0.00122	CcSEcCtD
Alprostadil—Loss of consciousness—Bupropion—obesity	0.0002	0.00122	CcSEcCtD
Alprostadil—Hypotension—Sibutramine—obesity	0.000199	0.00121	CcSEcCtD
Alprostadil—Cough—Bupropion—obesity	0.000198	0.00121	CcSEcCtD
Alprostadil—Convulsion—Bupropion—obesity	0.000197	0.0012	CcSEcCtD
Alprostadil—Hypertension—Bupropion—obesity	0.000196	0.00119	CcSEcCtD
Alprostadil—Dyspepsia—Orlistat—obesity	0.000193	0.00118	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Topiramate—obesity	0.000193	0.00118	CcSEcCtD
Alprostadil—Pollakiuria—Topiramate—obesity	0.000192	0.00117	CcSEcCtD
Alprostadil—Discomfort—Bupropion—obesity	0.000191	0.00116	CcSEcCtD
Alprostadil—Dry mouth—Bupropion—obesity	0.000189	0.00115	CcSEcCtD
Alprostadil—Pain—Orlistat—obesity	0.000188	0.00114	CcSEcCtD
Alprostadil—Hyperglycaemia—Topiramate—obesity	0.000187	0.00114	CcSEcCtD
Alprostadil—Dyspepsia—Sibutramine—obesity	0.000187	0.00114	CcSEcCtD
Alprostadil—Oedema—Bupropion—obesity	0.000185	0.00113	CcSEcCtD
Alprostadil—Infection—Bupropion—obesity	0.000184	0.00112	CcSEcCtD
Alprostadil—Shock—Bupropion—obesity	0.000182	0.00111	CcSEcCtD
Alprostadil—Renal failure—Topiramate—obesity	0.000182	0.00111	CcSEcCtD
Alprostadil—Pain—Sibutramine—obesity	0.000182	0.00111	CcSEcCtD
Alprostadil—Thrombocytopenia—Bupropion—obesity	0.000181	0.00111	CcSEcCtD
Alprostadil—Feeling abnormal—Orlistat—obesity	0.000181	0.0011	CcSEcCtD
Alprostadil—Tachycardia—Bupropion—obesity	0.000181	0.0011	CcSEcCtD
Alprostadil—Skin disorder—Bupropion—obesity	0.00018	0.0011	CcSEcCtD
Alprostadil—Urinary tract infection—Topiramate—obesity	0.00018	0.0011	CcSEcCtD
Alprostadil—Hyperhidrosis—Bupropion—obesity	0.000179	0.00109	CcSEcCtD
Alprostadil—Haematuria—Topiramate—obesity	0.000176	0.00108	CcSEcCtD
Alprostadil—Feeling abnormal—Sibutramine—obesity	0.000175	0.00107	CcSEcCtD
Alprostadil—Sinusitis—Topiramate—obesity	0.000174	0.00106	CcSEcCtD
Alprostadil—Abdominal pain—Orlistat—obesity	0.000174	0.00106	CcSEcCtD
Alprostadil—Body temperature increased—Orlistat—obesity	0.000174	0.00106	CcSEcCtD
Alprostadil—Hypotension—Bupropion—obesity	0.000173	0.00106	CcSEcCtD
Alprostadil—Bradycardia—Topiramate—obesity	0.000169	0.00103	CcSEcCtD
Alprostadil—Body temperature increased—Sibutramine—obesity	0.000168	0.00102	CcSEcCtD
Alprostadil—Abdominal pain—Sibutramine—obesity	0.000168	0.00102	CcSEcCtD
Alprostadil—Haemoglobin—Topiramate—obesity	0.000167	0.00102	CcSEcCtD
Alprostadil—Rhinitis—Topiramate—obesity	0.000167	0.00102	CcSEcCtD
Alprostadil—Haemorrhage—Topiramate—obesity	0.000166	0.00101	CcSEcCtD
Alprostadil—Hypoaesthesia—Topiramate—obesity	0.000165	0.00101	CcSEcCtD
Alprostadil—Pharyngitis—Topiramate—obesity	0.000165	0.001	CcSEcCtD
Alprostadil—Dyspepsia—Bupropion—obesity	0.000163	0.000994	CcSEcCtD
Alprostadil—Urethral disorder—Topiramate—obesity	0.000163	0.000993	CcSEcCtD
Alprostadil—Visual impairment—Topiramate—obesity	0.00016	0.000976	CcSEcCtD
Alprostadil—Pain—Bupropion—obesity	0.000158	0.000966	CcSEcCtD
Alprostadil—Asthenia—Orlistat—obesity	0.000158	0.00096	CcSEcCtD
Alprostadil—Pruritus—Orlistat—obesity	0.000155	0.000947	CcSEcCtD
Alprostadil—Flushing—Topiramate—obesity	0.000154	0.00094	CcSEcCtD
Alprostadil—Feeling abnormal—Bupropion—obesity	0.000153	0.00093	CcSEcCtD
Alprostadil—Asthenia—Sibutramine—obesity	0.000152	0.000929	CcSEcCtD
Alprostadil—Pruritus—Sibutramine—obesity	0.00015	0.000916	CcSEcCtD
Alprostadil—Diarrhoea—Orlistat—obesity	0.00015	0.000916	CcSEcCtD
Alprostadil—Abdominal pain—Bupropion—obesity	0.000146	0.000893	CcSEcCtD
Alprostadil—Body temperature increased—Bupropion—obesity	0.000146	0.000893	CcSEcCtD
Alprostadil—Diarrhoea—Sibutramine—obesity	0.000145	0.000886	CcSEcCtD
Alprostadil—Dizziness—Orlistat—obesity	0.000145	0.000885	CcSEcCtD
Alprostadil—Erythema—Topiramate—obesity	0.000145	0.000881	CcSEcCtD
Alprostadil—Dizziness—Sibutramine—obesity	0.000141	0.000857	CcSEcCtD
Alprostadil—Nervousness—Topiramate—obesity	0.00014	0.000856	CcSEcCtD
Alprostadil—Back pain—Topiramate—obesity	0.00014	0.000853	CcSEcCtD
Alprostadil—Muscle spasms—Topiramate—obesity	0.000139	0.000847	CcSEcCtD
Alprostadil—Rash—Orlistat—obesity	0.000138	0.000844	CcSEcCtD
Alprostadil—Dermatitis—Orlistat—obesity	0.000138	0.000843	CcSEcCtD
Alprostadil—Headache—Orlistat—obesity	0.000138	0.000838	CcSEcCtD
Alprostadil—Rash—Sibutramine—obesity	0.000134	0.000817	CcSEcCtD
Alprostadil—Dermatitis—Sibutramine—obesity	0.000134	0.000816	CcSEcCtD
Alprostadil—Anaemia—Topiramate—obesity	0.000134	0.000815	CcSEcCtD
Alprostadil—Headache—Sibutramine—obesity	0.000133	0.000811	CcSEcCtD
Alprostadil—Asthenia—Bupropion—obesity	0.000133	0.00081	CcSEcCtD
Alprostadil—Pruritus—Bupropion—obesity	0.000131	0.000799	CcSEcCtD
Alprostadil—Nausea—Orlistat—obesity	0.00013	0.000795	CcSEcCtD
Alprostadil—Syncope—Topiramate—obesity	0.00013	0.00079	CcSEcCtD
Alprostadil—Loss of consciousness—Topiramate—obesity	0.000127	0.000775	CcSEcCtD
Alprostadil—Diarrhoea—Bupropion—obesity	0.000127	0.000773	CcSEcCtD
Alprostadil—Nausea—Sibutramine—obesity	0.000126	0.000769	CcSEcCtD
Alprostadil—Cough—Topiramate—obesity	0.000126	0.000769	CcSEcCtD
Alprostadil—Convulsion—Topiramate—obesity	0.000125	0.000764	CcSEcCtD
Alprostadil—Hypertension—Topiramate—obesity	0.000125	0.000761	CcSEcCtD
Alprostadil—Dizziness—Bupropion—obesity	0.000123	0.000747	CcSEcCtD
Alprostadil—Discomfort—Topiramate—obesity	0.000122	0.000741	CcSEcCtD
Alprostadil—Dry mouth—Topiramate—obesity	0.00012	0.000734	CcSEcCtD
Alprostadil—Oedema—Topiramate—obesity	0.000118	0.000719	CcSEcCtD
Alprostadil—Infection—Topiramate—obesity	0.000117	0.000715	CcSEcCtD
Alprostadil—Rash—Bupropion—obesity	0.000117	0.000712	CcSEcCtD
Alprostadil—Dermatitis—Bupropion—obesity	0.000117	0.000711	CcSEcCtD
Alprostadil—Shock—Topiramate—obesity	0.000116	0.000708	CcSEcCtD
Alprostadil—Headache—Bupropion—obesity	0.000116	0.000707	CcSEcCtD
Alprostadil—Thrombocytopenia—Topiramate—obesity	0.000116	0.000704	CcSEcCtD
Alprostadil—Tachycardia—Topiramate—obesity	0.000115	0.000702	CcSEcCtD
Alprostadil—Skin disorder—Topiramate—obesity	0.000115	0.000699	CcSEcCtD
Alprostadil—Hyperhidrosis—Topiramate—obesity	0.000114	0.000695	CcSEcCtD
Alprostadil—Hypotension—Topiramate—obesity	0.00011	0.000672	CcSEcCtD
Alprostadil—Nausea—Bupropion—obesity	0.00011	0.000671	CcSEcCtD
Alprostadil—Dyspepsia—Topiramate—obesity	0.000104	0.000633	CcSEcCtD
Alprostadil—Pain—Topiramate—obesity	0.000101	0.000615	CcSEcCtD
Alprostadil—Feeling abnormal—Topiramate—obesity	9.73e-05	0.000593	CcSEcCtD
Alprostadil—Body temperature increased—Topiramate—obesity	9.33e-05	0.000569	CcSEcCtD
Alprostadil—Abdominal pain—Topiramate—obesity	9.33e-05	0.000569	CcSEcCtD
Alprostadil—Asthenia—Topiramate—obesity	8.47e-05	0.000516	CcSEcCtD
Alprostadil—Pruritus—Topiramate—obesity	8.35e-05	0.000509	CcSEcCtD
Alprostadil—Diarrhoea—Topiramate—obesity	8.08e-05	0.000492	CcSEcCtD
Alprostadil—Dizziness—Topiramate—obesity	7.81e-05	0.000476	CcSEcCtD
Alprostadil—Rash—Topiramate—obesity	7.44e-05	0.000454	CcSEcCtD
Alprostadil—Dermatitis—Topiramate—obesity	7.44e-05	0.000453	CcSEcCtD
Alprostadil—Headache—Topiramate—obesity	7.39e-05	0.000451	CcSEcCtD
Alprostadil—Nausea—Topiramate—obesity	7.01e-05	0.000427	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—IRS2—obesity	1.62e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGT—obesity	1.62e-05	0.000103	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—APOA1—obesity	1.61e-05	0.000102	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NCOA1—obesity	1.6e-05	0.000101	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOE—obesity	1.59e-05	0.000101	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LEP—obesity	1.59e-05	0.000101	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CD—obesity	1.59e-05	0.000101	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CD—obesity	1.59e-05	0.000101	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—STK11—obesity	1.58e-05	0.0001	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP19A1—obesity	1.58e-05	0.0001	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CAV1—obesity	1.57e-05	9.98e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—LPL—obesity	1.57e-05	9.97e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOA1—obesity	1.57e-05	9.96e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—obesity	1.57e-05	9.94e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FOXO1—obesity	1.56e-05	9.9e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—POMC—obesity	1.56e-05	9.9e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—POMC—obesity	1.56e-05	9.9e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IGF1—obesity	1.56e-05	9.89e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT2—obesity	1.56e-05	9.88e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRL—obesity	1.56e-05	9.87e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRL—obesity	1.56e-05	9.87e-05	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—obesity	1.54e-05	9.78e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STK11—obesity	1.53e-05	9.73e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STK11—obesity	1.53e-05	9.73e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL2—obesity	1.53e-05	9.68e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL2—obesity	1.53e-05	9.68e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PLG—obesity	1.52e-05	9.62e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—obesity	1.52e-05	9.62e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PLG—obesity	1.52e-05	9.62e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—RHOA—obesity	1.51e-05	9.6e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—RHOA—obesity	1.51e-05	9.6e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT2—obesity	1.5e-05	9.51e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT2—obesity	1.5e-05	9.51e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3R1—obesity	1.5e-05	9.5e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3R1—obesity	1.5e-05	9.5e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PRKCB—obesity	1.5e-05	9.5e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—F2—obesity	1.5e-05	9.5e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CD—obesity	1.5e-05	9.49e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE1—obesity	1.48e-05	9.39e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BAD—obesity	1.48e-05	9.39e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FOXO3—obesity	1.48e-05	9.39e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FOXO3—obesity	1.48e-05	9.39e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—obesity	1.48e-05	9.37e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRB2—obesity	1.48e-05	9.36e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRB2—obesity	1.48e-05	9.36e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—COMT—obesity	1.47e-05	9.3e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SOCS1—obesity	1.45e-05	9.22e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SOCS1—obesity	1.45e-05	9.22e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PRKCD—obesity	1.45e-05	9.18e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNB3—obesity	1.45e-05	9.17e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARGC1A—obesity	1.45e-05	9.17e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CD—obesity	1.44e-05	9.14e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CD—obesity	1.44e-05	9.14e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMOX1—obesity	1.44e-05	9.13e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SOCS3—obesity	1.44e-05	9.11e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SOCS3—obesity	1.44e-05	9.11e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CG—obesity	1.43e-05	9.09e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RHOA—obesity	1.43e-05	9.06e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IRS1—obesity	1.42e-05	8.99e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—obesity	1.42e-05	8.98e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3R1—obesity	1.41e-05	8.96e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS3—obesity	1.41e-05	8.96e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNAS—obesity	1.41e-05	8.93e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNB3—obesity	1.41e-05	8.92e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNB3—obesity	1.41e-05	8.92e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—TYK2—obesity	1.39e-05	8.79e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—TYK2—obesity	1.39e-05	8.79e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CB—obesity	1.38e-05	8.77e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CB—obesity	1.38e-05	8.77e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF2—obesity	1.38e-05	8.76e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF2—obesity	1.38e-05	8.76e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOB—obesity	1.38e-05	8.74e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—RHOA—obesity	1.38e-05	8.72e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—RHOA—obesity	1.38e-05	8.72e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNAS—obesity	1.37e-05	8.68e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNAS—obesity	1.37e-05	8.68e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—POMC—obesity	1.36e-05	8.65e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3R1—obesity	1.36e-05	8.63e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3R1—obesity	1.36e-05	8.63e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—INS—obesity	1.36e-05	8.61e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IRS2—obesity	1.35e-05	8.54e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOB—obesity	1.34e-05	8.5e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOB—obesity	1.34e-05	8.5e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL2—obesity	1.34e-05	8.47e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—obesity	1.33e-05	8.46e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOE—obesity	1.32e-05	8.36e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LPL—obesity	1.32e-05	8.35e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—obesity	1.31e-05	8.32e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT2—obesity	1.31e-05	8.32e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL5—obesity	1.31e-05	8.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL5—obesity	1.31e-05	8.3e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CAV1—obesity	1.31e-05	8.28e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CB—obesity	1.3e-05	8.27e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOA1—obesity	1.3e-05	8.26e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—obesity	1.28e-05	8.15e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LPL—obesity	1.28e-05	8.12e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LPL—obesity	1.28e-05	8.12e-05	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—obesity	1.28e-05	8.11e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FOXO1—obesity	1.27e-05	8.06e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FOXO1—obesity	1.27e-05	8.06e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RPS6KB1—obesity	1.27e-05	8.05e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RPS6KB1—obesity	1.27e-05	8.05e-05	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—obesity	1.26e-05	7.99e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CD—obesity	1.26e-05	7.99e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CB—obesity	1.26e-05	7.97e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CB—obesity	1.26e-05	7.97e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CD36—obesity	1.25e-05	7.93e-05	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—obesity	1.25e-05	7.92e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SERPINE1—obesity	1.25e-05	7.9e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BAD—obesity	1.23e-05	7.79e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TYK2—obesity	1.21e-05	7.69e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RHOA—obesity	1.2e-05	7.63e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3R1—obesity	1.19e-05	7.55e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOS3—obesity	1.19e-05	7.55e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—obesity	1.19e-05	7.52e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCD—obesity	1.18e-05	7.48e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCD—obesity	1.18e-05	7.48e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IRS1—obesity	1.18e-05	7.45e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARA—obesity	1.16e-05	7.37e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HTR2A—obesity	1.15e-05	7.32e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HTR2A—obesity	1.15e-05	7.32e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—C3—obesity	1.15e-05	7.31e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—C3—obesity	1.15e-05	7.31e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—obesity	1.13e-05	7.19e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AGT—obesity	1.13e-05	7.14e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—INS—obesity	1.13e-05	7.14e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOE—obesity	1.1e-05	7e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MTOR—obesity	1.1e-05	6.97e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CB—obesity	1.1e-05	6.97e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IRS2—obesity	1.1e-05	6.95e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IRS2—obesity	1.1e-05	6.95e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGT—obesity	1.1e-05	6.94e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGT—obesity	1.1e-05	6.94e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CAV1—obesity	1.09e-05	6.93e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOA1—obesity	1.09e-05	6.92e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—obesity	1.09e-05	6.91e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT2—obesity	1.09e-05	6.9e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LEP—obesity	1.07e-05	6.8e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOE—obesity	1.07e-05	6.8e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LEP—obesity	1.07e-05	6.8e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOE—obesity	1.07e-05	6.8e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CAV1—obesity	1.06e-05	6.74e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CAV1—obesity	1.06e-05	6.74e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOA1—obesity	1.06e-05	6.73e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOA1—obesity	1.06e-05	6.73e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CD—obesity	1.05e-05	6.63e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SERPINE1—obesity	1.03e-05	6.56e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—obesity	1.02e-05	6.5e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—obesity	1.02e-05	6.5e-05	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—obesity	1.02e-05	6.47e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—F2—obesity	1.01e-05	6.42e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—F2—obesity	1.01e-05	6.42e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCB—obesity	1.01e-05	6.42e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCB—obesity	1.01e-05	6.42e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TYK2—obesity	1.01e-05	6.38e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—obesity	1e-05	6.37e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BAD—obesity	1e-05	6.34e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BAD—obesity	1e-05	6.34e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RHOA—obesity	9.98e-06	6.33e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—obesity	9.96e-06	6.32e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3R1—obesity	9.87e-06	6.26e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS3—obesity	9.87e-06	6.26e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—obesity	9.68e-06	6.14e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—obesity	9.68e-06	6.14e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—obesity	9.61e-06	6.1e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IRS1—obesity	9.57e-06	6.07e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IRS1—obesity	9.57e-06	6.07e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—obesity	9.55e-06	6.06e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—POMC—obesity	9.48e-06	6.01e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—INS—obesity	9.43e-06	5.98e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—obesity	9.35e-06	5.93e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK8—obesity	9.29e-06	5.89e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—obesity	9.26e-06	5.87e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—POMC—obesity	9.22e-06	5.85e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—POMC—obesity	9.22e-06	5.85e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—INS—obesity	9.17e-06	5.81e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—INS—obesity	9.17e-06	5.81e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CB—obesity	9.11e-06	5.78e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTOR—obesity	9.11e-06	5.78e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—obesity	9.03e-06	5.73e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL2—obesity	9.02e-06	5.72e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL2—obesity	9.02e-06	5.72e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—obesity	8.87e-06	5.62e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—obesity	8.87e-06	5.62e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT2—obesity	8.86e-06	5.62e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT2—obesity	8.86e-06	5.62e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CD—obesity	8.76e-06	5.55e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—obesity	8.64e-06	5.48e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CD—obesity	8.51e-06	5.4e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CD—obesity	8.51e-06	5.4e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—obesity	8.49e-06	5.38e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—obesity	8.43e-06	5.35e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—obesity	8.43e-06	5.35e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SERPINE1—obesity	8.42e-06	5.34e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SERPINE1—obesity	8.42e-06	5.34e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3R1—obesity	8.27e-06	5.24e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NOS3—obesity	8.27e-06	5.24e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TYK2—obesity	8.19e-06	5.19e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TYK2—obesity	8.19e-06	5.19e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RHOA—obesity	8.12e-06	5.15e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RHOA—obesity	8.12e-06	5.15e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3R1—obesity	8.04e-06	5.1e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOS3—obesity	8.04e-06	5.1e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOS3—obesity	8.04e-06	5.1e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3R1—obesity	8.04e-06	5.1e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—obesity	7.95e-06	5.04e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—obesity	7.89e-06	5e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—obesity	7.87e-06	4.99e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—obesity	7.66e-06	4.86e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—obesity	7.66e-06	4.86e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CB—obesity	7.63e-06	4.84e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—obesity	7.56e-06	4.79e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CB—obesity	7.42e-06	4.71e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MTOR—obesity	7.42e-06	4.71e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CB—obesity	7.42e-06	4.71e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MTOR—obesity	7.42e-06	4.71e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—obesity	7.04e-06	4.47e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—obesity	6.89e-06	4.37e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—obesity	6.89e-06	4.37e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—obesity	6.78e-06	4.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—obesity	6.78e-06	4.3e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—obesity	6.7e-06	4.25e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—obesity	6.54e-06	4.15e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—obesity	6.53e-06	4.14e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—obesity	6.5e-06	4.12e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—obesity	6.45e-06	4.09e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—obesity	6.45e-06	4.09e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK8—obesity	6.27e-06	3.98e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK8—obesity	6.27e-06	3.98e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—obesity	6.26e-06	3.97e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—obesity	6.26e-06	3.97e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—obesity	5.93e-06	3.76e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—obesity	5.74e-06	3.64e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—obesity	5.74e-06	3.64e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—obesity	5.56e-06	3.52e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—obesity	5.47e-06	3.47e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—obesity	5.33e-06	3.38e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—obesity	5.33e-06	3.38e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—obesity	5.32e-06	3.37e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—obesity	5.32e-06	3.37e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—obesity	4.92e-06	3.12e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—obesity	4.65e-06	2.95e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—obesity	4.54e-06	2.88e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—obesity	4.52e-06	2.87e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—obesity	4.52e-06	2.87e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—obesity	4.01e-06	2.54e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—obesity	4.01e-06	2.54e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—obesity	3.8e-06	2.41e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—obesity	3.7e-06	2.34e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—obesity	3.7e-06	2.34e-05	CbGpPWpGaD
